The landscape of novel therapeutics and challenges in glioblastoma multiforme: contemporary state and future directions

K Khaddour, TM Johanns, G Ansstas - Pharmaceuticals, 2020 - mdpi.com
Background: Glioblastoma multiforme is a malignant intracranial neoplasm that constitutes a
therapeutic challenge because of the associated high morbidity and mortality given the lack …

Cell and tissue engineering in lymph nodes for cancer immunotherapy

AJ Najibi, DJ Mooney - Advanced drug delivery reviews, 2020 - Elsevier
In cancer, lymph nodes (LNs) coordinate tumor antigen presentation necessary for effective
antitumor immunity, both at the levels of local cellular interactions and tissue-level …

18F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immunotherapy

Y Feng, P Wang, Y Chen, W Dai - Nuclear Medicine …, 2023 - journals.lww.com
Objective This study aimed to investigate the relationship between 18 F-fluorodeoxyglucose
PET/computed tomography (18 F-FDG PET/CT) metabolic parameters and clinical benefit …

Perspectives for immunotherapy of EBV‐associated GLELC: A relatively “hot” tumor microenvironment

Y Lei, P Cao, X Zheng, J Wei, M Cheng… - Cancer Medicine, 2023 - Wiley Online Library
Abstract Background Epstein–Barr virus (EBV)‐associated gastric lymphoepithelioma‐like
carcinoma (EBVaGLELC) represents a small number of gastric cancer (GC), and research …

[HTML][HTML] Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy

Y Wang, T Zhu, Q Shi, G Zhu, S Zhu… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Tumor-draining lymph nodes (TDLNs) are potential immunotherapy targets that could
expand the population of patients with colorectal cancer (CRC) who may benefit from …

Insights and Opportunity Costs in Applying Spatial Biology to Study the Tumor Microenvironment

CR Walker, M Angelo - Cancer Discovery, 2024 - AACR
The recent development of high-dimensional spatial omics tools has revealed the functional
importance of the tumor microenvironment in driving tumor progression. Here, we discuss …

[HTML][HTML] Chemotherapy but not the tumor draining lymph nodes determine the immunotherapy response in secondary tumors

X Zhao, B Kassaye, D Wangmo, E Lou, S Subramanian - Iscience, 2020 - cell.com
Immunotherapies are used as adjuvant therapies for cancers. However, knowledge of how
traditional cancer treatments affect immunotherapies is limited. Using mouse models, we …

Expression of IDO1 and PD-L2 in patients with benign lymphadenopathies and association with autoimmune diseases

M Abdulla, C Sundström, C Lindskog, P Hollander - Biomolecules, 2023 - mdpi.com
The expression patterns of IDO1 and PD-L2 have not been thoroughly investigated in
benign lymphadenopathies. The aim with this study was to elucidate how IDO1 and PD-L2 …

Immune responses against disseminated tumor cells

L Peng, Y Zhang, Z Wang - Cancers, 2021 - mdpi.com
Simple Summary Metastasis in general represents the progression phenotype whereby
cancer cells break from a malignant primary location and travel to and invade other distant …

Incorporating Immunotherapy with Radiotherapy for Lymphomas

P Strati, MT Spiotto - Lymphatics, 2023 - mdpi.com
Radiotherapy and/or chemotherapy have been used for nearly 100 years to treat lymphoma.
Recently, immunotherapy has been incorporated into the treatment of lymphomas. Here, we …